Congress – less popular than dog poop!

Capitol HillOn becoming an American Citizen yesterday, one of my Facebook friends posted the following message on my wall – “WOOT WOOT!!!! NOW START COMPLAINING ABOUT CONGRESS!!!!”

However, it seems I will have to stand in line…as the rest of America has beaten me to it.

While the United States suffers through the second week of the federal shutdown, Public Policy Polling, a national survey agency, asked more than 500 registered voters if they liked various items more than they liked Congress.

HemorrhoidsThe results, showed that a mere 8% of those surveyed said they approved of the job Congress was doing, while 86% disapproved.

Onychomycosis1In addition to the aforementioned canine waste, voters also preferred hemorrhoids (53% vs 31%), toenail fungus (44% vs 41%) cockroaches (44% vs.42%), the IRS (42% vs. 33%), and the DMV (58% vs. 24%) to Congress.

But despite this, there is a glimmer of hope for lawmakers.

According to the survey, Americans still view Congress more favorably than the Ebola virus, Syria, Charles Manson, Lindsay Lohan, Honey Boo Boo, and twerking!

SRxA-logo for web

Potential treatment for Ebola and other deadly viruses revealed

Ebola virusIllnesses caused by many of the world’s most deadly viruses cannot be effectively treated with existing drugs or vaccines. But this may all be about to change. Scientists have discovered several compounds that can inhibit the highly lethal Ebola virus, as well as the pathogens responsible for rabies, mumps, measles and other pathogenic viruses.

This finding, published in the journal Chemistry & Biology potentially opens up new therapeutic avenues for combating these diseases.

ebola-patientSuch treatments are desperately needed. Ebola virus, for example, can be transmitted through direct contact with blood or other body fluids of infected persons or animals, and even close contact with a deceased Ebola-infected body. And mortality rates from ebola can be as high as 90%.

The medical field currently does not have ideal antiviral therapies, often no therapeutics at all, and the development of broad-spectrum antivirals is a great way to provide treatment in the future,” says study author Claire Marie Filone PhD of Boston University School of Medicine. “Toward that end, we have identified a drug that targets multiple viruses – and may be developed into an antiviral treatment for known and emerging viruses.”

In contrast to the many antibiotics that work against a wide range of bacteria, there are currently no highly effective or safe broad-spectrum drug treatments for viral diseases.

virus cycleTo address this need, researchers screened thousands of diverse compounds for small molecules that showed strong antiviral activity against viruses.  They identified several that inhibited infection in cells exposed to either Ebola or vesicular stomatitis virus (VSV). These molecules, which are related to a class of plant-derived compounds called indoline alkaloids, share a common chemical structure that can be modified to enhance antiviral activity.

The most potent of these compounds demonstrated a consistent mechanism of action against genetically distinct viruses. It works by blocking viral transcription. Because it targets such a critical step in virus replication, in theory, scientists should be able to develop it into a therapeutic that could be used against many different types of viral infections.

As always, SRxA’s Word on Health will bring you further news as it develops.

SRxA-logo for web

You Can Teach an Old Drug New Tricks

Drug discovery is a laborious process.

From initial discovery of a promising target to the final medication becoming available, is an expensive, and lengthy process. At present, the costs of bringing a single new drug to market is around $1.2 billion, an amount that doubles every five years.

Aside from the cost, it takes, on average, 12 years for an experimental drug to progress from bench through FDA approval to market.

Annually, North American and European pharmaceutical industries invest more than $40 billion to identify and develop new drugs. Even so, for every 5,000 compounds that enter pre-clinical testing, only five, on average, are tested in human trials, and only one of these five receives approval for therapeutic use.

So, it’s hardly surprising that many pharmaceutical companies are choosing to take a closer look at old drugs. Last week, SRxA’s Word on Health brought you news of a host of potential new uses for aspirin.

And aspirin is not alone.  Old drugs often get a surprising second shot at life. In the past few weeks, the news has buzzed about the skin cancer drug – bexarotene – that may cure Alzheimer’s; a common antimalarial drug – hydroxychloroquine – that may help to destroy cancerand, a leukemia drug that inhibits the Ebola virus.

Then, of course, there’s the personal favorite of many women – Latisse.  Originally developed as a glaucoma treatment , it was found to have the desirable side effect of making eyelashes fuller and longer and is now FDA approved for this purpose.

Testing drugs already approved for one use to see if they can treat other conditions, can reduce time and money. Since these known drugs have already undergone toxicology and safety testing, the clinical development program can be streamlined.

Sometimes it’s pure serendipity.

Take Viagra for example. Although these days it’s the stuff of pharmaceutical industry legend , in the early 1990s, it was just a chest pain drug that wasn’t performing very well in clinical trials. So how did the little blue pill go from heart to crotch?  Pfizer was ready to call it quits when they decided to look into one unexpected but common side effect: long-lasting erections. Then came the drug patent and the rest is history.

The discovery that lithium could be used to treat manic episodes in bipolar patients was equally fortuitous. In 1949, Australian psychiatrist John Cade was injecting guinea pigs with urine extracts from schizophrenia patients to try and isolate a compound that caused mental illness. By accident he happened to use a compound with lithium – which at the time was used as a treatment for gout, as the control. Although he didn’t find the compound that caused mental illness, he did find one that treated it!

Back in 2010 we reported on the repurposing of thalidomide. Although the drug caused serious birth defects when it was launched in the 1960’s as a morning sickness pill it has since been found to be useful in reducing severe and frequent bleeding in patients with  hemorrhagic telangiectasia (HHT); in the treatment of patients with newly diagnosed multiple myeloma when taken  in combination with dexamethasone; and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum

The National Institutes of Health (NIH) recently established The Learning Collaborative (TLC) to study how to more easily repurpose known drugs to treat rare forms of blood cancers.

TLC is a dedicated collaboration between the NIH Chemical Genomics Center (NCGC) and its Therapeutics for Rare and Neglected Diseases (TRND) program, The Leukemia & Lymphoma Society (LLS), and Kansas University Cancer Center (KUCC) to discover and develop new drug therapies for rare blood cancers. TLC is creating a pipeline of new therapies to treat leukemia from both the discovery of new treatments as well as identifying new uses for approved and abandoned drugs.  For example, Auranofin, a drug originally used for rheumatoid arthritis, is now in clinical trials for treating chronic lymphocytic leukemia.

Word on Health will continue to follow the drug recycling trend and bring you news as it breaks. In the meantime if you have noticed any beneficial side effects from the medicines you’re taking, we’d love to know.